AFT Pharmaceuticals - Expanded R&D pipeline to fuel LT growth
While AFT continues to gain commercial traction from Maxigesic/ Combogesic IV sales in the US (launched by partner Hikma in Q1 CY24) and...
315 Views
AFT Pharmaceuticals - Poised for international market expansion
AFT continues to focus on expanding its product portfolio and broadening its geographical footprint (including increased investments in its...
369 Views
AFT Pharmaceuticals - US milestone triggers upside and guidance bump
AFT Pharmaceuticals has announced the first sale of its intravenous pain relief medicine, Maxigesic IV, through its US licensing partner, Hikma...
445 Views
AFT Pharmaceuticals - A Bumpy Road
While it stated this was due to weaker-than-expected Australasian sales, relative to our expectations it was gross margins remaining soft.
305 Views
AFT Pharmaceuticals - US maiden voyage with Maxigesic IV launch
AFT Pharmaceuticals has announced the launch of Maxigesic IV, an intravenous form of its flagship pain relief prescription medicine, in the US...
243 Views